Category and country
Therapeutics companies in Finland
9 therapeutics profiles in Finland. Every profile is hand-reviewed with leadership, certifications, and public sources.
Where does therapeutics cluster in Finland?
Kuopio (3), Espoo (2), Helsinki (2), and Tampere (1) Most visible profiles: Aranda Pharma Ltd., Aurealis Therapeutics, Rokote Laboratories Finland, and StemSight Oy.
Which standards are already visible?
GMP (1) Latest review: 24 April 2026. Review cycle: April 2026.
Full list
Therapeutics profiles in Finland
9 profiles match the active filter.
Current review cycle
Aranda Pharma Ltd.
KuopioFinlandTherapeutics
Kuopio preclinical-stage pharma SME developing non-steroidal small-molecule androgen-receptor inhibitors for topical hair loss and acne treatments, with GLP safety studies via partners.
- Lead
- Mika KayhkoChief Executive Officer
- Scale
- Preclinical small-molecule development
Current review cycle
Aurealis Therapeutics
KuopioFinlandTherapeutics
Kuopio clinical-stage live-biotherapeutic company engineering lactic-acid bacteria to secrete therapeutic proteins, with lead candidate AUP-16 in Phase 1 for diabetic foot ulcers; group headquarters in Schlieren, Switzerland.
- Lead
- Juha YrjanheikkiChief Executive Officer and Co-Founder
- Scale
- Clinical-stage live-biotherapeutic development
Current review cycle
Rokote Laboratories Finland
KuopioFinlandTherapeutics
Finnish clinical-stage vaccine biotech developing a nasal adenoviral-vector COVID-19 vaccine and broader respiratory vaccine programs, with first-in-human trials underway at Kuopio University Hospital and partner GMP supply.
- Lead
- Erkko YlosmakiChief Executive Officer
- Scale
- Clinical-stage vaccine development
Current review cycle
StemSight Oy
TampereFinlandTherapeutics
Tampere advanced-therapy startup developing iPSC-derived corneal cell therapies, with lead indication limbal stem cell deficiency, moving toward ATMP and GMP manufacturing.
- Lead
- Laura KoivusaloChief Executive Officer and Co-Founder
- Scale
- Preclinical cell-therapy development
Current review cycle
Desentum
EspooFinlandTherapeutics
Espoo clinical-stage biopharmaceutical company developing next-generation allergen immunotherapy products from a Finnish operating base.
- Lead
- Pekka MattilaCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Aplagon
HelsinkiFinlandTherapeutics
Helsinki clinical-stage biopharmaceutical company developing APAC therapeutics for thromboinflammatory and vascular-occlusion diseases.
- Lead
- Aki PrihtiCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Valo Therapeutics
HelsinkiFinlandTherapeutics
Helsinki immunotherapy company developing antigen-coated oncolytic viruses and vaccine-vector platforms for cancer and infectious-disease treatment.
- Lead
- Paul HighamCEO
- Scale
- Clinical-stage therapeutics platform
Current review cycle
Herantis Pharma
EspooFinlandTherapeutics
Espoo therapeutics company developing biologic candidates for neuroinflammation and CNS disorders from a Finnish biotech platform.
- Lead
- Antti VuolantoCEO
- Scale
- Clinical-stage biotech therapeutics platform
Current review cycle
Faron Pharmaceuticals
TurkuFinlandTherapeutics
Turku immunotherapy headquarters advancing macrophage reprogramming and hematology-oncology programs through regulated clinical development.
- Lead
- Juho JalkanenChief Executive Officer
- Scale
- Clinical-stage therapeutic development
Related brief
Read deeper on this category
EU Biotech Regulation 2026: What Changed and Who It Affects
A plain reading of the 2026 EU biotech regulatory package — pharmaceutical reform, the European Health Data Space, the AI Act, and the upcoming EU Biotech Act — and what biotech, pharma, and CDMO companies should do about it.
Open briefFAQ
Frequently asked questions on this category
- What does "therapeutics company" mean?
- A company that develops drugs to treat or prevent disease, as distinct from contract manufacturers (CDMOs), service organizations (CROs), or tools/diagnostics suppliers. Therapeutic developers own a pipeline of drug candidates and either develop them in-house, license them out, or commercialize them at scale.
- Which European countries lead in therapeutics?
- Switzerland (Roche, Novartis, Idorsia, Basilea, Noema), Germany (BioNTech, Bayer, Merck KGaA), Denmark (Novo Nordisk, Lundbeck, Genmab, Zealand Pharma), Sweden (AstraZeneca, BioArctic, Sobi), and emerging markets in Poland (Ryvu, Captor), Lithuania (Atrandi, CasZyme), and Estonia (Asper Biogene). The directory covers all of these with hand-reviewed profiles.
- How are therapeutics companies verified in this directory?
- Every profile is hand-reviewed against an audit framework: leadership identity confirmed by primary source, physical site address sourced from official disclosures, regulatory and pipeline context backed by certification documents or filings, and a registry note explaining the company's current operating focus and clinical stage where applicable.
- Can I compare two therapeutic developers side by side?
- Yes — use the Compare button on any company card to add it to a comparison set (up to 3 companies), then open the /compare page for a side-by-side view of leadership, certifications, and operating scale.
Next step
Compare companies or open the wider market.
Use the compare tool to view two or three companies side by side, or open the country hub for the full market view.